Summary
New antigenic specificities, not detectable on parental cells, have been induced by many investigators in mouse lymphomas by treatment with the antitumor agent 5(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC). The antigens are transmissible, after withdrawal of the drug treatment, as an inheritable character. The mechanism of induction, the molecular nature, and the number of the new antigenic specificities have not been completely elucidated. Four clones from murine leukemia L1210 isolated and expanded in vitro were treated in vivo with DTIC and the new sublines were studied in detail. The four drug-treated sublines studied exhibited strong immunogenicity since they were rejected by syngeneic animals. Immunosuppressed animals challenged with 107 A/DTIC or P/DTIC cells were reciprocally protected by the adoptive transfer of spleen cells from donors that had rejected a lethal challenge of A/DTIC or P/DTIC clones. In a similar fashion, the adoptive transfer of spleen cells obtained from animals that had rejected the Q/DTIC or the R/DTIC clones protected immunosuppressed mice challenged with Q/DTIC or R/DTIC cells. No antitumor activity was observed in cross-protective schedules other than those indicated. It was been concluded that (a) the L1210 leukemia line does not have antigenic cells, (b) four DTIC-treated clone sublines were rejected by compatible hosts, and (c) two mutually exclusive sets of antigens were expressed in four antigenic clone sublines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bonmassar E, Bonmassar A, Vladamudi S, Goldin A (1970) Immunological alteration of leukemic cells “in vivo” after treatment with an antitumor drug. Proc Natl Acad Sci 66:1089
Bonmassar E, Bonmassar A, Vladamudi S, Goldin A (1972) Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno-4-carboxamide. Cancer Res 32:1446
Bonmassar E, Nicolin A, Spreafico F (1979) Drug-induced modifications of tumor cell antigenicity. Tumor-associated antigens and their specific immune response. In: Proceed Serono Symposia, 16:260
Boon T (1983) Antigenic tumor cell variants obtained with mutagens. Adv Cancer Res 39:121
Calman NS, Eng B, Slater LM, Wallerstein H (1974) Antigenic changes associated with resistance to methotrexate and 6-mercaptopurine in L1210 ascites lymphoma. J Natl Cancer Inst 52:997
Fuji H, Bernacki R, Mihich E (1974) Increased immunogenicity and antigenicity of L1210 lymphomas resistant to antileukemic agents as measured in vitro. Fed Proc 33:781
Giampietri A, Fioretti MC, Goldin A, Bonmassar E (1980) Drug mediated antigenic changes in murine leukemia cells: Antagonistic effect of quinacrine in antimutagenic compounds. J Natl Cancer Inst 64:297
Kitano M, Mihich E, Pressman D (1972) Antigenic differences between leukemia L1210 and a subline resistant to methylglyoxal-bis (guanylhydrazone). Cancer Res 32:181
Marelli O, Mantovani A, Franco P, Nicolin A (1982) Macrophage antitumor activity induced by the antigenic lymphoma L5178Y/DTIC subline. Tumori 68:365
Marelli O, Canti G, Franco P, Prandoni M, Ricci L, Nicolin A L1210/DTIC antigenic subline: studies at the clone level. Eur J Cancer (in press)
Mihich E (1969) Modfication of tumor regression by immunological means. Cancer Res 29:3345
Nicolin A, Bini A, Coronetti E, Goldin A (1974) Cellular immunoresponse to a drug-treated L5178Y lymphoma subline. Nature 251:654
Nicolin A, Canti G, Goldin A (1974) Adoptive immunotherapy in Balb/c × DBA/2CF1 mice bearing an immunogenic subline of L1210 leukemia. Cancer Res 34:3044
Nicolin A, Spreafico F, Bonmassar E, Goldin A (1976) Antigenic changes of L5178Y lymphoma after treatment with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide in vivo. J Natl Cancer Inst 56:89
Nicolin A, Franco P, Testorelli C, Goldin AM (1976) Immunosensitivity and histocompatibility antigens in drug-altered leukemic cells. Cancer Res 36:222
Nicolin A, Canti G, Marelli O, Veronese F, Goldin A (1981) Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines. Cancer Res 41:1358
Schmid FA, Hutchinson DJ (1973) Decrease in oncogenic potential of L1210 leukemia by triazenes. Cancer Res 33:2161
Schmid FA, Hutchinson DJ (1973) Decrease in oncogenic potential of L1210 leukemia by triazenes. Cancer Res 33:2161
Silvestrini R, Testorelli C, Goldin A, Nicolin A (1977) Cell kinetics and immunogenicity of lymphoma cells treated with (+(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC) in vivo. Int J Cancer 19:664
Spreafico F, Mantovani A, Menconi E (1974) Immunosuppressive activity of dimethyl-triazeno-imidazole-carboxamide (DTIC) in mice. Fed Proc 33:572
Testorelli C, Franco P, Goldin A, Nicolin A (1978) In vitro lymphocyte stimulation and the generation of cytotoxic lymphocytes with drug-induced antigenic lymphomas. Cancer Res 38:830
Author information
Authors and Affiliations
Additional information
Research supported in part by P.F.O. Contract Grant from C. N. R., Rome, Italy
Rights and permissions
About this article
Cite this article
Canti, G., Ricci, L., Marelli, O. et al. Adoptive immunity in mice challenged with L1210/DTIC clones. Cancer Immunol Immunother 24, 64–67 (1987). https://doi.org/10.1007/BF00199834
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00199834